Analyst
Evercore ISI
Equibles does not estimate personal net worth.
Umar Rafat is recorded as Analyst at Evercore ISI. Umar Rafat has spoken on 6 earnings calls across 4 companies, most recently for Elanco Animal Health Inc on August 5, 2026. Those appearances were for Elanco Animal Health Inc (ELAN), Phathom Pharmaceuticals, Inc. (PHAT), Bausch Health Companies Inc. (BHC) and Amgen Inc (AMGN). The companies whose calls Umar Rafat spoke on are classified in the Healthcare sector.
“I wanted to focus on OPEX for a quick second. So, top line is up 8% organically in 2Q and OPEX is up 10%. So, I guess my question to you is not even so much on operating leverage, it's really what are your plans on OPEX going forward in general?”
“I have a two-part question to go present today from a competitive dynamic perspective. First, just your overall thoughts on their data.”
“I wanted to touch up just broadly on your observations commercially with the readjusted commercial focus and what the feedback is and how much of a follow-through you guys are continuing to expect with the turnaround we're seeing on IMS already.”
“First, you're planning around separation, debt, refi, et cetera. How does that change, considering your current scenario is January 28th? How does that change if the D.C. Circuit Court reverses some of the prior findings of courts, and how does that change the level of urgency and planning?”
“Perhaps first, on gross margin, I thought I should dig into it a little more because if I step back and think about the $400 million plus in innovation growth in 2025, I would have thought there would be a gross margin expansion.”
Evercore ISI
Analyst
Transcript header (unverified)
Drug Manufacturers - Specialty & Generic · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
AMGN
Drug Manufacturers - General · Healthcare
